NEW YORK (AP) — Alexion Pharmaceuticals Inc. said Tuesday that regulators have designated its experimental drug asfotase alfa as a breakthrough therapy for a rare metabolic disease that can cause progressive damage to vital organs.

The Food and Drug Administration gives breakthrough therapy status to speed the development of drugs that treat serious or life-threatening illnesses if the new medication could be a major improvement over existing treatments.